| Literature DB >> 28144729 |
Shoko Ito1, Shin-Ichiro Fujiwara1, Kiyomi Mashima1, Kento Umino1, Daisuke Minakata1, Hirofumi Nakano1, Ryoko Yamasaki1, Yasufumi Kawasaki1, Miyuki Sugimoto1, Masahiro Ashizawa1, Chihiro Yamamoto1, Kaoru Hatano1, Kiyoshi Okazuka1, Kazuya Sato1, Iekuni Oh1, Ken Ohmine1, Takahiro Suzuki1, Kazuo Muroi1, Yoshinobu Kanda2.
Abstract
The development of acute myeloid leukemia (AML) in patients with untreated chronic lymphocytic leukemia (CLL) is rare. We experienced a 65-year-old man who developed AML with aberrant CD7 expression and monoallelic CEBPA mutation during watchful waiting for CLL. He failed to achieve complete response (CR) by standard induction therapy for AML. We retrospectively reviewed 27 patients who developed AML with untreated CLL published between 1973 and 2016. The median age at diagnosis of AML was 68 years, and the median duration between the diagnoses of AML and CLL was 4.2 years. Diagnosis of AML and CLL was made simultaneously in 16 patients. The CR rate of AML was 42.9%, and the median survival was only 1.5 months after the diagnosis of AML. Patients who achieved CR tended to survive longer than those who did not. Our results demonstrated that the development of AML in patients with untreated CLL was associated with a poor response to chemotherapy and an extremely poor prognosis.Entities:
Keywords: Acute myeloid leukemia; Chemotherapy; Chronic lymphocytic leukemia; Secondary leukemia
Mesh：
Substances：
Year: 2017 PMID： 28144729 DOI： 10.1007/s00277-017-2933-x
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673